推荐最近最火的赌博软件 ALS 研究 and Treatment Center

Call to Request an Appointment

315-464-4243

推荐最近最火的赌博软件's ALS 研究 and Treatment Center provides evidence-based, multidisciplinary ALS care and services for patients with ALS and related motor neuron diseases in a supportive atmosphere with an emphasis on hope and quality of life.

The clinic team consists of ALS specialized doctors, 肌萎缩性侧索硬化症研究人员, 护士, clinic coordinator/social worker, 营养师, 呼吸治疗师, 物理治疗师, 职业治疗师, speech language pathologist, spiritual palliative care, representatives from MDA and ALS association.

推荐最近最火的赌博软件's comprehensive care involves multiple specialties, so patients may receive multiple services at one visit. It is the largest ALS Center in New York outside of New York City, and a referral center for central and western New York State. The Center is located at UHCC and sees patients on a weekly basis.

国家认可

The Center is nationally recognized for its research into possible treatments for ALS, and patients are given the opportunity to participate in a variety of clinical trials.

The Center is one of only a handful of centers that have received certification by both the Muscular Dystrophy Association and the ALS Association. The ALS Clinic at 推荐最近最火的赌博软件 is part of the ALS Association's national network of Certified Treatment Centers of Excellence in Clinical Care and 研究.

推荐最近最火的赌博软件-Spirometry through Telemedicine in ALS

家肺量测定法

A study measuring the use of home-spirometry compared to hospital-based spirometry for accuracy and efficacy in measuring respiratory decline using telemedicine.

网站π: Dr. Eufrosina年轻
研究协调员: 莉娜·黛布((电子邮件保护); 315-464-9756)
临床试验.gov标识符: NCT05106569

目前招聘

HEALEY ALS Platform Trial

This is the first ALS platform trial, accelerating the path to new ALS therapies by testing multiple treatments at once, reducing the cost of research by 30%, decreasing the trial time by 50% and increasing patient participation by 67%

网站π: Dr. E. 年轻的
研究协调员: 莉娜·黛布((电子邮件保护); 315-464-9756)
临床试验.gov标识符: NCT04297683

目前招聘 for Regimen F only

COMBAT-ALS

A phase 2b/3 Multi-center, 随机, 双盲, 安慰剂对照, 12 month clinical trial to evaluate the efficacy and safety of MN-166 (ibudilast) followed by an open-label extension in subjects with ALS.

A study measuring the safety and efficacy of Ibudilast (MN-166) for use in ALS. This drug has already shown promise in ALS in its phase 2 trial in improving patient’s functional activity, quality of life and muscle strength.

网站π: Dr. 珍妮迈耶
研究协调员: 锡吉里亚·斯莫伦((电子邮件保护); 315-464-9767)
临床试验.gov标识符: NCT04057898

目前招聘

COURAGE-ALS

A第3期, 多中心, 双盲, 随机, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with ALS.

Reldesemtiv acts on your muscles to strengthen contraction. Reldesemtiv has been tested in humans extensively and it showed promise in an earlier ALS trial. During the second half of the study, all patients will receive the active drug.

网站π: Dr. 黛博拉·布拉德肖
研究协调员: 锡吉里亚·斯莫伦((电子邮件保护); 315-464-9767)
临床试验.gov标识符: NCT04944784

目前招聘